-+ 0.00%
-+ 0.00%
-+ 0.00%

TME Pharma announces availability of CEO shareholder letter

PUBT·09/16/2026 06:00:42
Listen to the news
TME Pharma announces availability of CEO shareholder letter
  • TME Pharma NV released a shareholder letter from CEO Diede van den Ouden outlining strategy, financing discipline, and partnering plans.
  • Management said cost cuts since June 2025 extended cash runway to Q2 2027, with limited dilution since December 2024 via classic bond financing.
  • The letter said talks continue on a NOX-A12 licensing deal, aiming to secure Phase 2 GLORIA execution and shareholder economics tied to peak sales.
  • It also flagged potential value creation beyond core biotech assets, citing the holding-company structure and NOX-E36 as a continuing opportunity.
  • Direct letter link: https://ml-eu.globenewswire.com/Resource/Download/568caa08-1348-4767-8335-49a36d8f3902


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TME Pharma NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160200OMX_____CNEWS_FR_GNW1001262930_fr) on September 16, 2026, and is solely responsible for the information contained therein.